CSIMarket
 


Denali Therapeutics Inc   (DNLI)
Other Ticker:  
 

Denali Therapeutics Inc 's Leverage Ratio

DNLI's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 3.81%, Leverage Ratio fell to 0.12, below the Denali Therapeutics Inc 's average Leverage Ratio.

Within Biotechnology & Pharmaceuticals industry in the forth quarter 2023, 3 other companies have achieved lower Leverage Ratio than Denali Therapeutics Inc in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 64, from total ranking in the third quarter 2023 at 119 .

Explain Leverage Ratio?
Who are DNLI Customers?
What are DNLI´s Total Liabilities?


DNLI Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change -1.1 % 37.84 % 34.19 % 5.31 % 8.33 %
Y / Y Total Liabilities Change -70.57 % -71.55 % -70.86 % 9.85 % -5.44 %
Leverage Ratio MRQ 0.12 0.11 0.1 0.46 0.4
DNLI's Total Ranking # 64 # 119 # 117 # 746 # 404
Seq. Equity Change -7.81 % -5.77 % 22.77 % -7.26 % 28.49 %
Seq. Total Liabilities Change 3.81 % -0.39 % -73.14 % 5.94 % 0.36 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 18
Overall Market # 64


Leverage Ratio Statistics
High Average Low
0.51 0.32 0.1
(Sep 30 2022)   (Jun 30 2023)




Financial Statements
Denali Therapeutics Inc 's Equity $ 1,031 Millions Visit DNLI's Balance sheet
Denali Therapeutics Inc 's Total Liabilities $ 123 Millions Visit DNLI's Balance sheet
Source of DNLI's Sales Visit DNLI's Sales by Geography


Cumulative Denali Therapeutics Inc 's Leverage Ratio

DNLI's Leverage Ratio for the trailling 12 Months

DNLI Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth -1.1 % 37.84 % 34.19 % 5.31 % 8.33 %
Y / Y Total Liabilities TTM Growth -70.57 % -71.55 % -70.86 % 9.85 % -5.44 %
Leverage Ratio TTM 0.19 0.25 0.35 0.45 0.45
Total Ranking TTM # 1 # 173 # 4 # 958 # 414
Seq. Equity TTM Growth -7.81 % -5.77 % 22.77 % -7.26 % 28.49 %
Seq. Total Liabilities TTM Growth 3.81 % -0.39 % -73.14 % 5.94 % 0.36 %


On the trailing twelve months basis Despite of the net new borrowings of 3.81% during the twelve months period ending in IV Quarter 2023 Denali Therapeutics Inc has managed to decrease Leverage Ratio in the IV Quarter 2023 to 0.19, below Denali Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry DNLI recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 1, from total ranking in previous 12 month period at 173.

Explain Leverage Ratio?
Who are DNLI Customers?
What are DNLI´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 1
Within the Market # 1


trailing twelve months Leverage Ratio Statistics
High Average Low
0.47 0.34 0.17
(Sep 30 2022)   (Dec 31 2018)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Iovance Biotherapeutics Inc   0.32 $ 187.961  Millions$ 584.613  Millions
Exelixis Inc   0.30 $ 678.445  Millions$ 2,263.912  Millions
Adverum Biotechnologies Inc   0.30 $ 24.914  Millions$ 83.469  Millions
Bio techne Corp  0.30 $ 582.231  Millions$ 1,963.559  Millions
Dbv Technologies S a   0.27 $ 37.696  Millions$ 140.187  Millions
Replimune Group Inc   0.26 $ 111.393  Millions$ 421.537  Millions
Allogene Therapeutics inc   0.25 $ 130.604  Millions$ 512.233  Millions
Twist Bioscience Corporation  0.24 $ 142.773  Millions$ 590.042  Millions
Vir Biotechnology Inc   0.21 $ 328.824  Millions$ 1,590.236  Millions
Anavex Life Sciences Corp   0.18 $ 24.073  Millions$ 135.575  Millions
Caribou Biosciences Inc   0.17 $ 63.808  Millions$ 368.401  Millions
Voyager Therapeutics Inc   0.17 $ 39.721  Millions$ 236.320  Millions
Fresh Tracks Therapeutics Inc   0.17 $ 1.656  Millions$ 9.930  Millions
Springworks Therapeutics Inc   0.16 $ 99.569  Millions$ 626.219  Millions
Molecular Partners Ag  0.12 $ 21.923  Millions$ 176.429  Millions
Denali Therapeutics Inc   0.12 $ 122.963  Millions$ 1,030.954  Millions
Entera Bio Ltd   0.10 $ 0.989  Millions$ 10.386  Millions
Krystal Biotech Inc   0.05 $ 39.714  Millions$ 778.641  Millions
Immunovant Inc   0.05 $ 31.796  Millions$ 679.344  Millions
Estrella Immunopharma Inc   0.04 $ 0.399  Millions$ 9.049  Millions

Date modified: 2024-02-28T20:36:20+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com